Supervisor Database Search

Guidance for ICAT Supervisors

The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.

You can read about the ICAT supervisor selection process and eligibility criteria below:

Terms of reference/guide to supervising ICAT Fellows.

You can read the terms of reference for supervisors actively supervising ICAT Fellows below:

Supervisor Database

Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

← Go back

Full NameProfessor Stephen Pennington

School of Medicine

University College Dublin

Webpage:www.ucd.ie

Email hidden; Javascript is required.

Research Fields

genetics, genomics and molecular biology
cell and developmental biology/regenerative medicine
physiology and non-communicable disease
cancer/oncology
clinical trials

Postgrad Medical Specialties

Medicine
Surgery
General Practice
Pathology
Public Health

Medical Subspecialties

Cardiology
Community Medicine
Geriatric Medicine
Health Informatics
Immunology
Oncology
Pharmacology
Physiology
Rheumatology

My Work

We are engaged in the application of the latest developments in proteomics strategies to the elucidation of disease mechanisms and identification of disease markers to make significant advances in personalised medicine by identifying and developing protein biomarkers to support patient stratification.

We are currently active in two major disease areas:

i) prostate cancer (see: Tonry C et al. The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. Diagnostics. 2016, 6: 27; Staunton L et al, Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LC-MS EuPA Open Proteomics. 2016, 10:19-23.; Tonry CL, et al. Discovery and Longitudinal Evaluation of Candidate Protein Biomarkers for Disease Recurrence in Prostate Cancer. J Proteome Res. 2015, 14:2769-83)

ii) inflammatory arthritis (see: McArdle et al. Developing Clinically Relevant Biomarkers in Inflammatory Arthritis: A Multi-Platform Approach for Serum Candidate Protein Discovery. Proteomics Clin Appl. 2015 doi: 10.1002/prca.201500046; Mc Ardle A et al.. Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. Arthritis Res Ther. 2015, 17:141. Ademowo OS, et al. Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Ann Rheum Dis. 2014 doi: 10.1136/annrheumdis-2014-205417.)

We are particularly interested in translating our lab-based research findings to clinical utility (see: Hernandez B, Pennington SR, Parnell AC. Bayesian methods for proteomic biomarker development. EuPA Open Proteomics. 2015, 9:54-64; Percy et al.. Clinical Translation of MS-based Quantitative Plasma Proteomics: Status, Challenges, Requirements, and Potential. Expert Rev Proteomics. doi: 10.1080/14789450.2016.1205950) and have recently founded a small company - Atturos - to support this endeavour (www.atturos.com).